The National Pharmaceutical Council (NPC) submitted feedback to the Institute for Clinical and Economic Review’s (ICER) request for comment as it looks to update its value assessment framework.
NPC in its comments proposed a “collaborative and transparent model development process.”
“NPC also encouraged ICER to more frequently utilize real-world evidence, which shows how treatments may work in patients under everyday conditions,” NPC said in an email. “In recent years, there’s been enormous growth in the availability of high-quality, real-world data sources, improvements in analytic models and broader use of real-world evidence derived from this data.”
To read NPC’s comments, click here.